Peter Attia· MD
if you occupy the FK the r the fkbp with fk506 Romy has nothing to act on in your mouth and you'll prevent this
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
if you occupy the FK the r the fkbp with fk506 Romy has nothing to act on in your mouth and you'll prevent this
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
if you occupy the FK the fkbp of FK 506 rapamycin has nothing to act on in your mouth and you'll prevent this because as far as I know fk56 does not do this and so you just need to occupy or even with a benign arapomycin-like molecule all you need is an fkbp binder to sop up The Binding sites that rapamycin would use
why don't people do FK 506 mouthwashes I don't get this right because all you need to do is occupy Stuart Schreiber showed this I don't know ages ago right if you occupy the FK the fkbp of FK 506 rapamycin has nothing to act on in your mouth and you'll prevent this
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.